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INTRODUCTION
Osteoporosis is defined as a skeletal disorder characterized
by compromised bone strength predisposing a person to an
increased risk of fracture (1). Bone mass accounts for approx-
imately 70% of bone strength. At menopause, an uncoupling
of bone remodeling, in which bone resorption exceeds bone
formation, results in progressive bone loss and postmenopausal
osteoporosis. It has been supposed that both the interleukin
(IL) -1 family of cytokines and the IL-6 system may be involv-
ed in bone remodeling. IL-1 , IL-1 , and IL-6 are believed
to be potent stimulators of bone resorption (2). Cytokine
activity depends on the balance with natural modulators.
IL-1 receptor antagonist (IL-1ra) is a competitive inhibitor
of IL-1, and soluble IL-6 receptor (sIL-6r) acts as an agonist
of IL-6. However, clinical studies on the possibility of involve-
ment of these cytokines in the development of postmenopausal
osteoporosis have led to contradictory results (3-9). Some of
the conflict in results may be due to the differences in method-
ology of sample collections. A lot of advantages of whole
blood cell culture in measuring cytokine secretion have recently
been demonstrated, compared with serum measurement, or
peripheral blood monocyte culture (10). Zheng et al. (11)
reported that IL-1 and IL-6 production by whole blood cells
was higher in osteoporotic postmenopausal women than in
normal healthy women, but they did not adjust IL-1 pro-
duction to total cell counts, and did not measure the level of
IL-1 , IL-1ra, and sIL-6r. The balance between IL-1 and IL-
1ra, and that between IL-6 and soluble IL-6 receptor are im-
portant to understand a whole picture of these IL systems’
effects.
We have recently demonstrated that the cytosine-adenine
(CA) polymorphism in the insulin-like growth factor-I (IGF-
I) gene is associated with serum IGF-I levels (12). Similarly,
polymorphisms within the cytokine genes may be genetic
basis for the cytokine production by whole blood cells. Recently,
a number of polymorphism in human IL-1 system and IL-6
gene have been reported: the C-889T polymorphism in the
IL-1 gene (13), the C-511T polymorphism in the promoter
region of IL-1 gene (14), the 86 base pair (bp) variable num-
ber tandem repeat (VNTR) in intron 2 of the IL-1ra gene
(15) and the C-634G polymorphism in the promoter region
of IL-6 gene (16) etc. The significance of these polymorphisms
in terms of protein production by whole blood cells has not
yet been determined. The aims of the present study were to
investigate the relationship between the production of IL-1 ,
IL-1 ‚ IL-1ra, IL-6, and soluble IL-6 receptor by whole blood
cells, and bone mineral density (BMD) in postmenopausal
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Cytokine Production by Whole Blood Cells: Relationship to Interleukin
Gene Polymorphism and Bone Mass
The aims of this study were to investigate the relationships between the production
of interleukin-1 (IL-1), and IL-6 system by whole blood cells, and bone mineral den-
sity (BMD), and polymorphisms in IL-1 system and IL-6 gene in postmenopausal
Korean women. The production of IL-1 , IL-1 , IL-1 receptor antagonist (IL-1ra),
IL-6, and soluble IL-6 receptor (sIL-6r) by lipopolysaccharide-stimulated whole blood
cells was measured by ELISA in 110 subjects. Serum osteocalcin, C-telopeptide
of type I collagen, and BMD at lumbar spine and proximal femur were measured.
IL-1 C
-889T polymorphism, IL-1 C
-511T polymorphism, 86-base pair variable num-
ber tandem repeat polymorphism in the IL-1ra gene, and IL-6 C
-634G polymorphism
were analyzed. The production of IL-1 correlated positively with BMD at femoral
neck, whereas the production of other ILs did not correlate with BMD at the skele-
tal sites examined. No significant differences in the production of ILs were observed
among normal, osteopenic and osteoporotic postmenopausal women, and among
the different IL system polymorphisms groups studied. No correlation between bone
turnover markers and the production of ILs was noted. In conclusion IL-1 may
regulate bone metabolism at femoral neck, and the IL system polymorphism do not
affect the production of ILs by whole blood cells. 
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Korean women and to evaluate whether IL system gene poly-
morphisms affect the production of ILs by whole blood cells. 
MATERIALS AND METHODS
Study subjects 
This study included 110 postmenopausal women, between
the ages of 48 and 65 yr, who visited the Menopause Clinic
of Seoul National University Hospital for bone mass exami-
nation, and who agreed to participate in the study. All of the
subjects had been without spontaneous menses for at least
one year. They underwent a careful physical examination,
and a medical history review. Blood glucose, and hepatic and
renal functions were determined. Women who had under-
gone bilateral oophorectomy or women with current hepatic
disease, renal disease or diabetes mellitus were excluded. None
of the subjects had received any medication known to affect
bone metabolism before the study. All subjects gave their
informed consent, and the study protocol was approved by
the Institutional Review Board of Seoul National Universi-
ty Hospital.
Measurements of BMD and body mass index (BMI)
BMD was measured in grams per square centimeter at the
lumbar spine (L2-L4), femoral neck, trochanter, and Ward’s
triangle, using a Lunar DPX-L dual-energy radiography ab-
sorptiometer (Lunar Radiation Corp., Madison, WI, U.S.A.),
and categorized into three groups according to the World
Health Organization’s criteria (17) as, normal, osteopenic, or
osteoporotic, relative to the means and standard deviation of
young adult Korean women. The in vivo coefficient of varia-
tion was 1.4% for the lumbar spine, 2.1% for the femoral
neck, 1.1% for the trochanter, and 2.1% for Ward’s trian-
gle. BMI was calculated by dividing body weight (kg) by
the square of body height (m2).
Whole blood cells cultures
Blood samples were collected, from all subjects in accor-
dance with the guidelines of the Declaration of Helsinki,
with endotoxin free vacuum blood collection tubes contain-
ing preservative free heparin, and total number of monocytes
and lymphocytes were counted. Blood was diluted 1/10 in
RPMI (Gibco, Grand Island, NY, U.S.A.) complemented
with 2 mM glutamine, 100 U/mL penicillin, 100  g/mL
streptomycin, 0.25  g/mL amphotericin B and transferred
into Falcon culture tubes with or without lipopolysaccharide
(LPS) (Sigma, St Louis, MO, U.S.A.) at a final concentration
of 25  g/mL. Culture tubes were then incubated for 2 days
at 37℃ in a 5% CO2 atmosphere. After incubation, samples
were centrifuged at 800×g for 10 min, supernatants were
collected, and frozen at -20℃until assay for ILs.
Measurements of IL-1 , IL-1 , IL-1ra, IL-6, and sIL-6r in
culture supernatant
IL-1 , and IL-1ra were measured using a quantitative sand-
wich immunoassay kit purchased from R & D systems (Min-
neapolis, MN, U.S.A.). The minimum detection limit was
1 pg/mL for IL-1 , and 14 pg/mL for IL-1ra. Intra- and inter-
assay variations for IL-1 were 3.8% and 5.2%, respectively.
Intra- and inter-assay variations for IL-1ra were 4.0% and
5.1%, respectively. IL-1 and IL-6 were measured using an
enzyme linked immunosorbent assay kit purchased from
Chemicon International Inc. (Temecula, CA, U.S.A.). The
minimum detection limit was 0.195 ng/mL for IL-1 and
IL-6. Intra- and inter-assay variations for IL-1 were 8.1%
and 11.7%, respectively. Intra- and inter-assay variations for
IL-6 were 7.0% and 11.3%, respectively. sIL-6r was measured
using an enzyme linked immunosorbent assay kit purchased
from Bender MedSystems (Vienna, Austria). The minimum
detection limit was 0.02 ng/mL for sIL-6r. Intra- and inter-
assay variations for sIL-6r were 1.7% and 2.2%, respectively.
The resulting IL levels were then corrected for total mono-
cyte and lymphocyte cell numbers. The values given are quoted
in ng or pg/mL/106 cells.
Measurements of serum bone turnover markers 
Serum osteocalcin (OST) was measured using a competi-
tive radioimmunoassay kit (Techno Genetics, Milano, Italy),
with a minimum detection limit of 0.1 nM/L. The intra- and
inter-assay variations for OST were 4.0% and 5.1%, respec-
tively. Serum carboxy-terminal C-telopeptide of type I col-
lagen (CrossLaps; CTX) was measured using a serum CTX
one step enzyme-linked immunosorbent assay kit (Osteome-
ter Biotech, Herlev, Denmark), with a minimum detection
limit of 94 pM/L, and intra- and inter-assay variations were
5.4% and 5.1%, respectively.
Determination of the IL-1 system and IL-6 gene polymor-
phisms
Genomic DNA was extracted from peripheral blood leuko-
cytes using a QiaAmp blood kit (Qiagen GmbH, Hilden,
Germany). The 86 bp VNTR polymorphism of the IL-1ra
was analyzed as previously described (14, 15). A1 allele (four
repeats) was 410 bp, A2 allele (two repeats) 240 bp, A3 allele
(five repeats) 495 bp, and A4 allele (three repeats) 325 bp.
The 304 bp fragment of genomic DNA containing the AvaI
polymorphic portion at position -511 (C-511T) relative to the
start site of transcription of the IL-1 gene was amplified by
polymerase chain reaction (PCR), as described by Chen et al.
(14). To analyze the NcoI polymorphic site at position -889
(C-889T) of the IL-1 gene, the 99 base fragment was ampli-Cytokine Production, Bone Mass & Polymorphism  1019
fied by PCR using the same oligonucleotide primers and
PCR reaction steps previously described by McDowell et al.
(13). To analyze the BsrBI polymorphic site at position -634
(C-634G) in the promoter of the IL-6 gene, PCR amplifications
were carried out as described previously by Ota et al. (16).
After PCR products were digested with restriction enzymes,
the digests were separated on agarose gels. The absence of
the AvaI, NcoI, and BsrBI sites was designated as the A, N,
and B allele, respectively, and the presence of these restriction
cutting sites was designated as a, n, and b allele, respectively.
Statistical analysis 
All data are expressed as the mean±SE. Statistical analy-
sis was performed using the SAS statistical program (SAS
Institute, Cary, NC, U.S.A.). The genotype frequencies for
each polymorphism against Hardy-Weinberg ratios were
assessed by the  2-test or Fisher’s exact test. Differences in
anthropometric characteristics between the different IL geno-
types were tested using one way analysis of variance (ANOVA)
followed by Tukey’s test, or using Student’s t-test. Similar
comparisons were made for BMD, the serum levels of bone
turnover markers, or for the production of ILs by whole blood
cells using Student’s t-test, or after adjusting potential con-
founding factors, such as age, and years since menopause, by
analysis of covariance (ANCOVA). To assess the relationship
between the production of ILs by whole blood cells and BMD,
simple regression analysis was performed and Pearson’s cor-
relation coefficient was then calculated. A pvalue of less than
0.05 was considered significant for all analyses.
RESULTS
Table 1 shows the cytokine production by whole blood
cells and serum levels of bone turnover markers in normal,
osteopenic, and osteoporotic postmenopausal women. LPS
treatment induced an increase in the production of IL-1 ,
IL-1 , IL-6, and sIL-6r by whole blood cells and an increased
IL-1 /IL-1ra ratio. After adjusting for potential confound-
ing factors, such as age, and years since menopause, no sig-
nificant differences were observed in the basal production of
IL-1 , IL-1 , IL-1ra, IL-6, or sIL-6r by whole blood cells,
or in the IL-1 /IL-1ra ratio among normal, osteopenic, and
Postmenopausal women
Normal (n=30) Osteopenia (n=46) Osteoporosis (n=34) p
Age (yr)  54.3±0.7
� ,� 57.3±0.6
� ,� 61.0±0.7
� ,� 0.001
Years since menopause 5.4±0.6
‖,¶ 8.2±0.5
‖,** 12.5±0.9
¶,** 0.001
BMI (kg/m
2) 24.3±0.4 24.7±0.3 24.3±0.4 0.64
IL-1 (pg/mL/10
6 cells)* Basal 1.8±0.1 2.3±0.4 1.9±0.1 0.38
Stimulated 296.9±18.5 283.8±14.8 302.9±24.5 0.75
IL-1 (ng/mL/10
6 cells)* Basal 0.4±0.1 0.4±0.1 0.3±0.0 0.32
Stimulated 14.1±1.8 12.2±1.0 11.1±1.2 0.31
IL-1ra (pg/mL/10
6 cells)* Basal 1741.4±220.1 1827.6±182.2 1709.9±256.2 0.92
timulated 6721.8±612.9 8731.5±2971.2 5878.2±307.5 0.59
IL -1 /IL-1ra* Basal 0.5±0.1 0.3±0.0 0.3±0.0 0.10
Stimulated 2.5±0.3 2.7±0.3 2.2±0.3 0.39
IL-6 (ng/mL/10
6 cells)* Basal 6.4±3.4 2.7±0.3 4.1±1.3 0.36
Stimulated 19.4±1.2 18.4±0.9 20.3±2.4 0.67
IL-6r (ng/mL/10
6 cells)* Basal 7.5±0.5 7.7±0.3 8.3±0.4 0.37
Stimulated 29.4±20.0 24.7±14.8 10.0±0.3 0.63
CTX (pM/L)* 2268.9±377.8 2920.3±349.3 3730.8±627.0 0.10
Osteocalcin (ng/mL)* 13.0±0.6
� � 15.2±0.9
� � 32.8±6.9
� � ,� � 0.001
Table 1. Cytokine production from whole blood cells and serum levels of bone turnover markers  in normal, osteopenic, and osteoporotic
postmenopausal women
*Values are adjusted for age, years since menopause and expressed as mean±SE. 
BMI, body mass index; IL, Interleukin; IL-1ra, IL-1 receptor antagonist; sIL-6r, soluble IL-6 receptor; CTX, CrossLaps.
p, ANCOVA; 
� ,� ,�
, p<0.01; 
‖, p<0.05; 
¶,**, p<0.001; 
� � ,� �
, p<0.05 (by Tukey’s test).
IL, interleukin; IL-1ra, IL-1 receptor antagonist; sIL-6r, soluble IL-6
receptor. *, p<0.05.
IL-1 IL-1ra IL-6 sIL-6r IL-1 IL-1 /
IL-1ra
Age 0.07 0.05 0.12 -0.13 0.11 -0.09
Years since MP -0.02 -0.01 0.01 -0.13 0.04 -0.08
Body mass index  0.19* 0.06 0.07 -0.10 -0.01 -0.04
Osteocalcin 0.03 -0.01 0.05 0.06 -0.08 0.01
CrossLaps -0.05 -0.14 -0.06 0.06 -0.12 -0.01
Lumbar spine 0.03 0.10 0.08 -0.12 -0.08 0.09
Femoral neck 0.11 0.16* 0.08 0.11 0.10 -0.05
Ward’s triangle 0.01 0.07 0.01 0.06 -0.01 -0.06
Trochanter 0.07 0.11 0.04 -0.01 0.10 -0.09
Table 2. Correlation coefficients between bone mineral density,
bone turnover markers and cytokine production from lipopolysac-
charide-stimulated whole blood cells (n=110)1020 J.G. Kim, S.Y. Ku, K.S. Lim, et al. 
osteoporotic postmenopausal women and this trend persist-
ed even in the LPS stimulation. The production of IL-1 by
LPS-stimulated whole blood cells correlated positively with
BMD at the femoral neck (r=0.16, p<0.05), whereas the pro-
duction of IL-1 , IL-1ra, IL-6, sIL-6r, and the IL-1 /IL-1ra
ratio did not correlate with BMD at the skeletal sites exam-
ined (Table 2). There were no significant correlations between
IL system components and bone turnover markers such as
osteocalcin and CTX.
Four alleles in the IL-1ra VNTR polymorphism were ob-
served: A1 96.4%; A2 1.8%; A3 1.4%; A4 0.4%. When
study subjects were grouped according to carriage of the A2
allele, two genotypes were noted: the heterozygotes, A1A2,
A3A2, (3.6%) and the noncarriage group, i.e., A1A1, A1A4,
and A3A3 (96.4%). The distributions of the IL-1 NcoI, IL-
1 AvaI, and IL-6 BsrBI polymorphisms were as follows; nn
85.5%, Nn 13.6%, NN 0.9%, aa 35.5%, Aa 50.9%, AA
13.6%, bb 6.4%, Bb 34.5%, and BB 59.1% respectively.
These IL system allele frequencies followed the Hardy-Wein-
berg equilibrium. As shown in Table 3, regardless of LPS
stimulation, the production of IL-1 , IL-1 , IL-1ra, IL-6,
or sIL-6r by WBCs and the IL-1 /IL-1ra ratio were not dif-
ferent according to IL-1 , IL-1 or IL-1ra genotypes. IL-6
genotypes did not affect the production of IL-6, and sIL-6r
by whole blood cells (Table 4).
DISCUSSION
A central role of immune system has been suggested in
bone remodeling through proinflammatory cytokines. In
the present study, we investigated the relationships among
the production of interleukin-1 and IL-6 system by whole
blood cells, and bone mass, and polymorphisms in IL-1 sys-
tem and IL-6 genes in postmenopausal Korean women. To
the best of our knowledge, this is the first report of its kind
that have comprehensively analyzed about IL-1 , IL-1 , IL-
1ra, IL-6, sIL-6r levels and IL-1 NcoI, IL-1 AvaI, IL-1ra
A2, IL-6 BsrBI polymorphism. 
It has been suggested that IL system may be implicated
in the pathogenesis of postmenopausal osteoporosis. How-
ever, no differences has been noted in the circulating levels
of IL-1 , IL-1 , IL-1ra (3), or IL-6 (4) or in the production
of IL-1 by peripheral blood monocytes (5-6) between osteo-
porotic postmenopausal women and normal postmenopausal
women, although some researchers have reported contradic-
tory findings (7-9). Recently, Zheng et al. (11) reported that
IL-1 and IL-6 production by mitogen-stimulated whole
blood cells was higher in osteoporotic postmenopausal women
than in normal postmenopausal women, and that lumbar
BMD correlated negatively with IL-1 production. In the
present study, regardless of LPS stimulation, we were unable
to find any differences in the production of IL-1 , IL-1 , or
IL-1ra, IL-6 or sIL-6r by WBCs, or in the IL-1 /IL-1ra ratios
between osteoporotic postmenopausal women and normal
postmenopausal women. A number of possible reasons may
IL-1 NcoI
nn (n=94) p Nn (n=15)
IL-1 AvaI
aa (n=39) Negative
(n=106)
Positive
(n=4)
p p Aa (n=56) AA (n=15)
IL-1ra   A2 allele
IL-1 (pg/mL/10
6 cells)
Basal 2.0±0.2 2.7±0.7 0.25 1.9±0.1 2.3±0.3 1.9±0.1 0.49 2.1±0.2 1.9±0.2 0.86
Stimulated 291.8±11.7 303.1±31.6 0.27 261.7±17.4 317.4±16.3 278.8±22.7 0.07 287.7±10.3 240.1±62.3 0.42
IL-1 (ng/mL/10
6 cells)
Basal 0.4±0.1 0.4±0.1 0.69 0.4±0.1 0.4±0.1 0.4±0.1 0.91 0.4±0.1 0.4±0.1 0.88
Stimulated 12.2±0.8 11.5±1.7 0.27 10.4±0.9 13.8±1.1 9.9±1.6 0.06 11.8±0.7 7.4±2.2 0.29
IL-1ra (pg/mL/10
6 cells)
Basal 1817.9±144.1 1478.7±189.6 0.64 1677.6±170.3 1896.5±212.3 1563.4±212.2 0.59 1722.0±119.7 2732.5±1833.1 0.18
Stimulated 7286.2±1421.8 7004±1100.5 0.95 5412.7±302.8 6410.3±394.4 13864.9±7652.6 0.06 7281.9±1355.4 3445.2±496.4 0.61
IL-1 /IL-1ra
Basal 0.33±0.03 0.4±0.2 0.57 0.4±0.1 0.3±0.1 0.3±0.1 0.76 0.3±0.0 0.2±0.1 0.56
Stimulated 2.56±0.18 2.3±0.5 0.87 2.4±0.2 2.6±0.2 2.0±0.4 0.41 2.5±0.2 2.7±1.1 0.79
Table 3. Cytokine production from whole blood cells in relation to IL-1 NcoI, IL-1 AvaI, and IL-1ra polymorphism
Values are adjusted for age, and years since menopause, and expressed as  mean±SE.
IL- 1ra, IL-1 receptor antagonist; sIL-6r, soluble IL-6 receptor; IL-1ra A2 negative: A1A1, A1A4, A3A3; IL-1ra A2 positive: A1A2, A3A2.
Values are adjusted for age, years since menopause, and expressed
as mean±SE. 
IL- 1ra, IL-1 receptor anatagonist; sIL-6r, soluble IL-6 receptor; p, ANOVA.
IL-6 BsrBI
bb (n=7) Bb (n=38) BB (n=65) p
IL-6 (ng/mL) (pg/mL/10
6 cells)
Basal 3.0±0.6 4.0±1.2 4.5±1.7 0.94
Stimulated 16.5±1.7 21.3±2.0 18.3±0.8 0.21
sIL-6r (ng/mL) (ng/mL/10
6 cells)
Basal 7.7±0.8 7.8±0.4 7.9±0.3 0.96
Stimulated 9.2±0.7 10.0±0.4 31.7±15.4 0.43
Table 4. Cytokine production from whole blood cells in relation
to IL-6 BsrBI polymorphism be proposed to explain the discrepancy of results between
our study and that of Zheng et al. (11). First, they did not
adjust the measured IL levels to total cell counts, whereas we
did. Second, the whole blood cells culture time is relatively
shorter in their study (1 day) than in our study (2 days), and
it has been reported that the production of IL-1 and IL-2
reaches a maximum around 2-4 days after the start of whole
blood cells culture (10). Third, they used both phytohemag-
glutinin and LPS, whereas we used LPS only. Finally, the
number of study subjects in our study was twice as many as
that from the report by Zheng et al. (11). 
In the present study, IL-1 production by LPS-stimulated
whole blood cells correlated positively with BMD of femoral
neck. This finding suggests that high IL-1 does not always
have a resorptive effect on all skeletal mass. This hypothesis
is supported by recent findings that high cytokine produc-
tion by peripheral blood monocytes is related with greater
BMD gain in femoral neck, but greater bone loss in spinal
bone (18). This possible site-specific skeletal effect of a cer-
tain cytokine needs to be elucidated by further studies.
Genotype frequencies of the IL-1 system genes in our sub-
jects differ from those reported in Caucasians. The aa geno-
type of the IL-1 gene is less common than in Caucasians
(35.5% vs. 43.4%) (19), and the NN the genotype of the IL-
1 gene and A2 allele of the IL-1ra gene in Koreans were
very rare, compared to Caucasians (13, 15). The distributions
of IL-6 BsrBI genotypes in Koreans are similar to those pre-
viously reported in Japanese women (20). No differences
were found in the production of IL-1 , IL-1 , or IL-1ra by
whole blood cells, or the IL-1 /IL-1ra ratios among IL-1 sys-
tem genotypes, although other investigators (18) have report-
ed that the presence of the IL-1ra A2 allele is associated with
an enhanced IL-1 and IL-1ra production, and a reduced
IL-1 production by peripheral blood monocytes. These dis-
crepancies may be due to differences in methodology of sam-
ple collection. In addition, there was no association of IL-6
genotypes with the production of IL-6 and sIL-6r in the pre-
sent study.
Three types of sampling methods have been used to mea-
sure cytokine secretion; serum measurement, peripheral blood
monocyte culture and whole blood cells culture. Of these
methods, whole blood cells culture does not disturb the con-
centrations of circulating factors and the ratios of different
cells, which may be important for normal molecular and intra-
cellular interactions. Moreover, it has the advantage of being
much quicker and simpler than peripheral blood monocyte
culture, and is less likely to result in the contamination of
samples. 
In conclusion, IL-1 may regulate bone metabolism at
femoral neck and IL polymorphisms do not affect the produc-
tion of ILs by whole blood cells. Systemic ILs production by
whole blood cells may not reflect the status of the cytokine
production in the bone microenvironment. And thus, further
cross-sectional and longitudinal studies are needed on the
relationship between bone mass and cytokine production in
the microenvironment of bone marrow.
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